FierceBiotechOriginal article
{"a":[{"_":"Beeline flies into phase 3 as oral lupus drug soars past placebo","$":{"href":"/biotech/beeline-flies-phase-3-oral-lupus-drug-soars-past-placebo","hreflang":"en"}}]}
Phase 2positiveafimetoranPositive
AI Analysis
Summary
Beeline Medicines' afimetoran achieved its primary endpoint in a phase 2 trial for lupus, positioning the company to advance into phase 3 development for multiple lupus indications.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Primary endpoint hit in phase 2 trial
Importance:7/10
Sentiment:
0.80
phase_2lupusprimary_endpointoral_drugphase_3_advance
Read the original article
Published by FierceBiotech on September 9, 2026 4:23 AM